workplace drug testing Australia Archives

The Sober Check Guide to Workplace Drug Testing in Australia

24July202624 July 2026 Becks Stratton

Here’s something that happens more often than it should:

An employer in Queensland or WA receives a positive drug test result for a safety-critical worker, moves to stand them down, and then discovers (when the worker challenges the decision) that the testing programme they’ve been running for three years doesn’t actually comply with the relevant Australian standard.

The result may be given significantly less weight or be challenged because the employer cannot demonstrate that the testing process complied with recognised procedures. The worker stays, and the employer has just learned a very expensive lesson about the difference between having a testing programme and having a compliant one.

That gap (as in between going through the motions and actually doing this properly) is what this overview is about.

What is Workplace Drug Testing?

At its core, workplace drug and alcohol testing is about managing the safety risk that substance use (and/or abuse) creates, and looking after the health and well-being of all staff.

One important point to understand from the outset is that workplace drug testing generally measures drug exposure rather than impairment. The period over which drug exposure can be detected varies depending on the specimen type used. Test results should always be interpreted alongside the workplace policy, the circumstances of the test and any applicable legislation.

That sounds straightforward. But in practice, it actually sits inside a broader legal and operational framework that a surprising number of businesses haven’t thought through carefully.

The testing itself is one piece. The policy that defines what’s prohibited and what happens when someone tests positive is another thing entirely.

Another is the training that equips supervisors to identify potential impairment and initiate a reasonable cause test. The chain-of-custody documentation that makes a result defensible if it ends up before the Fair Work Commission is another issue. Pull any one of those pieces out and the programme has a hole in it. Consent plays a critical role in this from an employee standpoint

Where urine drug testing is used, the technical benchmark in Australia is AS/NZS 4308:2023, which is the Australian and New Zealand urine standard updated in 2023 after fifteen years on the 2008 version.

It sets the cut-off concentrations for screening, defines when a result is considered not-negative, establishes specimen collection procedures, outlines laboratory requirements and details the chain of custody processes needed to maintain the integrity of a result.

Legal Requirements by State

One of the things that catches Australian employers off guard is discovering that drug and alcohol testing compliance doesn’t look the same in every state:

Western Australia

If there’s a state in Australia where employers have genuinely internalised the idea that drug and alcohol testing is non-negotiable, it’s WA.

The resources sector here dominates the entire conversation and the Mines Safety and Inspection Act 1994 and the Work Health and Safety (Mines) Regulations 2022 along with the Work Health and Safety Act 2020 (WA) create a framework where fitness for work programmes are a core requirement of this critical sector.

For any business contracting into WA mining, oil and gas or resources operations, a compliant testing programme is typically a contractual condition before a single worker mobilises to site.

Principal contractors don’t wait to be asked. They require demonstrated compliance upfront. Pre-employment testing, random testing, post-incident testing, and reasonable cause testing together constitute the full suite.

Queensland

Queensland’s resources sector operates under the Coal Mining Safety and Health Act 1999 and the Mining and Quarrying Safety and Health Act 1999, with Resources Safety and Health Queensland overseeing compliance.

Fitness-for-work requirements (which, yes, include systematic drug and alcohol testing) are embedded in the safety and health management system obligations that mine operators must maintain.

Outside the resources sector, Queensland employers are operating under the Work Health and Safety Act 2011 (Qld) and the general duty to manage impairment risks. Construction and transport businesses in Queensland increasingly find that major project requirements effectively mandate a testing programme, whether the base legislation requires one or not.

Principal contractors specify it as a site condition and businesses that can’t demonstrate a compliant programme don’t get on-site.

New South Wales

NSW adopted the model WHS legislation, with SafeWork NSW administering it. Drug testing is often mandatory or legally justified under the Work Health and Safety Act 2011 (NSW), which obliges employers – known as Persons Conducting a Business or Undertaking (PCBUs) – to manage safety risks, including impairment.

What NSW does have, however, is a significant body of Fair Work Commission case law around drug testing and dismissal. NSW employers have been through a lot of contested termination cases involving positive drug tests. We see a pattern emerging from case law that is consistent: Fair Work decisions consistently consider whether employers followed their own policy, used a fair process and were able to demonstrate the integrity of the testing process.

Victoria

Victoria kept its own legislation; the Occupational Health and Safety Act 2004 (Vic). This was when most other states adopted the harmonised model WHS Act.

The practical obligations around impairment risk management are similar, but the regulatory culture has its own characteristics too. For instance, large construction projects in Victoria operate under enterprise agreements that have historically included specific procedural requirements around testing that go beyond the regulatory minimum.

For Victorian construction employers, that means the industrial instrument sitting over their workforce can impose requirements around how testing is conducted, who can administer it and how results are handled that aren’t immediately obvious from reading the OHS Act alone.

South Australia

South Australian employers use workplace drug and alcohol testing as one of a number of controls to manage impairment risks under Work Health and Safety Act 2012 (SA). Whether testing is appropriate depends on the risks within the workplace, but where testing is introduced it should be supported by clear policies and procedures and carried out in accordance with the relevant Australian Standards.

Tasmania

In Tasmania, workplace drug and alcohol testing is used as one of several controls to manage impairment risks under the Work Health and Safety Act 2012 (Tas). Testing should form part of a broader workplace health and safety programme that includes clear policies, worker education, supervisor training and appropriate support for employees where required.

Like the rest of Australia, testing should be proportionate to the workplace risks and developed in consultation with workers. Employers should also recognise that most drug testing identifies drug exposure rather than impairment and should ensure policies clearly explain how test results will be interpreted and managed.

For more detailed guidance, refer to the official WorkSafe Tasmania standards on managing drugs and alcohol.

Australian Capital Territory

In the Australian Capital Territory, workplace drug and alcohol testing is governed by the Work Health and Safety Act 2011, which places the onus on employers to manage safety risks. Testing should be proportionate to the workplace risks and supported by consultation with workers. ACT employers in high-risk industries such as construction and transport frequently implement testing regimes as a critical safety control. To remain compliant, these policies must be developed in genuine consultation with workers and must clearly demonstrate that the testing is a necessary measure to ensure a safe working environment. For a deeper understanding of these obligations, you can review the ACT Work Health and Safety standards and employer guidelines.

Northern Territory

In the Northern Territory, workplace drug and alcohol testing is underpinned by the Work Health and Safety (National Uniform Legislation) Act 2011, which requires a Person Conducting a Business or Undertaking (PCBU) to eliminate or minimise risks to health and safety so far as is reasonably practicable. The WHS Act section 19 establishes a clear duty of care for employers to manage impairment risks, particularly in safety-critical sectors such as mining and transport.

Mining, construction, transport and remote operations commonly implement workplace drug and alcohol testing as part of their fitness for work programmes. As with other jurisdictions, employers should ensure testing is supported by documented policies, appropriate consultation and recognised Australian Standards.

Workplace Drug Testing Methods

The choice of testing method shapes everything from what the programme can actually detect to how collections are conducted in the field:

Urine Testing (AS/NZS 4308:2023)

Urine testing remains the most widely used workplace drug testing method in Australia and is the primary specimen type covered in AS/NZS 4308:2023. Workplace drug testing detects drug exposure rather than impairment. This distinction is important when developing workplace policies and interpreting results.

The detection window is longer than oral fluid (cannabis metabolites can show up in urine for days to weeks, depending on frequency of use, for instance), which alone makes urine testing effective for identifying historical use rather than just recent impairment.

Laboratory confirmation of not-negative screening results is required, and the chain-of-custody requirements for urine specimen collection are detailed and non-negotiable for a defensible result.

AS/NZS 4308:2023: specimen collection, detection and quantification of drugs in urine.

Oral Fluid Testing (AS/NZS 4760:2019)

Saliva testing has grown substantially in workplace use because it solves the practical problems that urine testing creates in field environments. No bathroom facilities are required, it is less invasive and results are available quickly on-site.

The detection window is shorter, which is actually an advantage when the goal is identifying recent use, rather than whether someone smoked cannabis at a weekend party three weeks ago.

The devices used for oral fluid screening must meet the performance criteria in AS/NZS 4760:2019, and a not-negative screening result should be sent for laboratory confirmation in accordance with AS/NZS 4760:2019 and workplace policy.

AS/NZS 4760:2019: specimen collection and detection of drugs in oral fluid.

Breath Alcohol Testing (AS 3547:2019)

Breath alcohol testing is commonly conducted alongside drug testing as part of a workplace drug and alcohol programme, but it operates differently from urine or oral fluid drug testing.

AS 3547:2019 relates to the performance of breath alcohol testing devices rather than prescribing the complete workplace testing procedure. Employers should therefore ensure they are using a workplace breathalyser that meets the relevant requirements of AS 3547:2019, while also having clear procedures covering how alcohol testing is conducted, documented and managed.

Collector competency is another important consideration. The current Australian unit of competency, HLTPAT010: Collect specimens for drugs of abuse testing, covers the skills and knowledge required to conduct urine, oral fluid and breath testing. It includes preparing for collection, following appropriate procedures, maintaining documentation and chain of custody, and using compliant equipment.

Breathalysers need to be properly calibrated and maintained, with the administration procedure followed correctly to produce a reliable result.

Alcohol continues to be one of the most common causes of impairment in Australian workplaces as a primary ‘drug of choice’, so if a drug testing programme doesn’t also address alcohol, it has a significant gap.

AS 3547:2019: performance requirements for breath alcohol testing devices.

Collector competency: HLTPAT010 – Collect specimens for drugs of abuse testing. the current Australian unit covering urine, oral fluid and breath collection/testing.

How to Implement a Workplace Testing Programme

The businesses that end up in trouble with their testing programmes are almost never the ones that deliberately cut corners. They’re usually the ones who bought a testing kit, wrote a policy based on something they found online, and assumed that was enough.

A defensible programme starts with policies and procedures that have actually been written with the intent of managing the risks associated with drug and alcohol use in the workplace (not a generic template) that clearly define how these risks are controlled. These are some of the types of elements to be considered based on guidelines from SafeWork NSW.

Develop clear policies and procedures relating to alcohol and other drugs in the workplace.
Train managers and supervisors to identify signs of impairment and the appropriate action to take.
Educate workers on the risks associated with alcohol and drug use. This could include recognising signs of impairment and how to report concerns within the workplace.
Manage psychosocial hazards and risks that could contribute to alcohol or drug use. For example, managing high workloads.
Develop clear policies and procedures relating to the PCBUs response to others being impaired and creating risks in the workplace. For example, managing members of the public demonstrating signs of impairment.
Develop an alcohol and drug testing programme such as random testing, pre-employment testing and post-incident testing (ensuring you also comply with privacy and other laws). If testing is being considered as a control measure, legal advice may be required.

Every worker needs to have read it, understood it as well as sign something that documents that understanding.

One more thing: collector qualifications matter more than most employers appreciate. Under AS/NZS 4308:2023, collectors need to meet competency requirements. An unqualified person who’s following the instructions on a testing kit is not a compliant collector, and that distinction is going to become very important when a result is challenged. Competency should also be maintained through ongoing training and regular assessment.

Why Quality Control Matters

One of the biggest changes introduced by AS/NZS 4308:2023 is the requirement for ongoing quality control of on-site urine drug testing devices.

Employers conducting on-site testing are expected to verify device performance through routine high and low control testing, maintain documented quality records and have procedures for managing failed quality control events.

This represents a significant shift from simply purchasing compliant testing devices to actively demonstrating that those devices continue to perform correctly throughout their use.

For workplaces managing their own testing programme, quality control is now an essential part of maintaining compliance rather than an optional extra.

Choosing the Right Workplace Drug Testing Solution

When implementing a workplace drug and alcohol testing programme, employers generally have two options: manage testing in-house or engage a third-party testing provider. The right approach depends on the size of the organisation, the number of tests conducted each year, available resources and operational requirements.

In-house Workplace Testing

Many organisations choose to manage drug and alcohol testing internally because it provides greater flexibility, faster response times and can significantly reduce ongoing testing costs. Instead of paying call-out fees and service charges for every test, organisations invest in compliant testing devices and train their own personnel to carry out testing when and where it is needed.

An effective in-house programme relies on more than selecting the right testing devices. Employers also need documented procedures, compliant chain-of-custody processes, quality control measures and staff who are confident using the equipment correctly.

Sober Check Australia supports organisations implementing in-house testing programmes by supplying compliant drug and alcohol testing devices, providing product training, assisting with testing procedures and offering ongoing technical support to help workplaces build a programme that aligns with the relevant Australian Standards.

Third-Party Testing Services

For organisations that don’t have the resources or desire to conduct testing internally, a third-party provider may be the preferred option. While this generally involves a higher ongoing cost and may not provide the same immediate response as an in-house programme, employers are paying for the convenience of experienced collectors managing the testing process.

When selecting a third-party provider, employers should ensure they operate in accordance with the relevant Australian Standards, use appropriately trained collectors, maintain documented chain-of-custody procedures and utilise NATA-accredited laboratories for confirmatory testing where required.

Finding the Right Partner

Whether you’re introducing an in-house programme or reviewing your current approach, it’s important to work with a provider who understands the practical requirements of Australian workplaces.

Sober Check Australia supports organisations across all Australian states and territories with compliant drug and alcohol testing products, product training, technical advice and practical guidance to help workplaces implement effective testing programmes.

If it’s time to establish a workplace drug and alcohol testing programme (or review whether your current programme meets today’s standards) our team is here to help.

Get in touch today to discuss the best solution for your workplace.

A Sober Check Guide to Australian Workplace Drug & Alcohol Policy

22July202622 July 2026 Becks Stratton

Let’s be honest about something; most workplace drug and alcohol policies are terrible.

Not terrible in a dramatic or even in a legally explosive way, but nonetheless terrible in the way that makes experienced HR managers quietly cringe. They’re copy-pasted from somewhere on the internet, stuffed with language nobody actually speaks and then they’re filed away in a shared drive that hasn’t been opened since the document was created.

Half the workforce doesn’t even know the policy exists and the other half signed something at induction and immediately forgot about it!

Then something happens on site. Someone turns up clearly impaired. A post-incident test comes back positive. A manager has to make a call in real time, under pressure and in front of other workers… and there’s no clear procedure to follow because the policy is either non-existent, out of date or written so vaguely it could mean almost anything.

That’s the gap this guide is designed to close. Not just having a policy, but having one that actually does something.

Why Every Workplace Needs a Drug and Alcohol Policy (A Real One)

Safe Work Australia is pretty unambiguous on this point. Managing impairment risk is part of an employer’s primary duty of care under work health and safety legislation of the relevant state or territory. State regulations also provide practical guidance, such as the Queensland Government’s guidance on managing alcohol and other drugs in the workplace (here is the Queensland government’s guidance on this).

The obligation isn’t to have a document. It’s to identify the hazard, assess the risk and to put controls in place. A written policy is the foundation of that.

What is surprising for a lot of employers is the fact that not having a policy isn’t simply a gap in compliance, it is a potential liability for your business or organisation. If a worker is injured and there’s no documented policy, no testing procedure and no evidence that the organisation took the risk seriously, this could become an important consideration during a WorkSafe or workers’ compensation investigation, depending on the circumstances.

And without a written and properly implemented framework, every situation becomes a discretionary call made by whoever happens to be the supervisor on the day. Two workers, same behaviour, different managers, completely different outcomes. That’s how discrimination claims start. That’s how unfair dismissal cases get traction. A consistent approach provides protection for employers and employees alike.

For anyone who’s in construction, mining, transport or utilities, a drug and alcohol policy isn’t optional at all. Principal contractors routinely require subcontractors to have one before a worker sets foot on site. Some federal and state regulatory frameworks make it a condition of operating.

Scope That Covers Everyone: What Do Policies Typically Include

The policy has to be clear about who it applies to and the answer should be everyone. Full-time staff, casuals, contractors, labour hire workers and in some circumstances, visitors.

Policies that only technically cover direct employees tend to develop gaps exactly where the risk is highest, simply because in a lot of Australian workplaces, a significant portion of the workforce isn’t on a direct employment contract.

The policy should also identify who is responsible for implementing it, including managers, supervisors, contractors, workers and any third-party providers involved in testing.

The Prescription Medication Problem

Most policies either ignore this entirely or handle it so awkwardly that it creates more confusion than clarity.

But here’s the practical reality; workers have a right to privacy around their medical treatment, but they also have a safety obligation. Someone who is operating a forklift while taking a medication that causes significant drowsiness is a hazard, regardless of whether the medication is legal and legitimately prescribed.

A workable policy creates a confidential disclosure process. Workers notify a nominated person (typically HR or an occupational health contact) and not their direct supervisor. The conversation is about managing the safety risk and not interrogating someone’s medical history.

Reasonable adjustments might be available. The goal is to keep the person safe and keep them working, not to punish someone for having a health condition.

The same principles may also apply to over the counter medications that have the potential to impair a person’s ability to work safely.

Cut-Off Levels That Match the Standard

This is the technical piece that many policy templates skip over; however, it matters enormously. If the workplace conducts testing (more on that below), the cut-off concentrations in the policy need to align with AS/NZS 4308:2023 for urine testing and AS/NZS 4760:2019 if they are doing oral fluid testing. Where breathalysers are used, they should comply with AS 3547:2019 (Breath Alcohol Testing Devices).

If a workplace policy references outdated standards, it should be reviewed and updated. Policies don’t need to reproduce the technical requirements contained within the standard, but they should reference the current versions and ensure workplace procedures align with them.

Testing (When, How and What Happens Next)

The policy needs to spell out the testing framework in plain language. What triggers a test? Pre-employment screening, random testing, reasonable cause and post-incident testing…each is a different situation with a different process, so the policy should address them separately.

Random testing, in particular, is an area where vague policy language causes real operational headaches. “Random testing may be conducted from time to time” is not a testing programme.

A defensible random testing framework should specify the selection methodology, frequency of testing, who administers the tests, which devices are used and how a not-negative screening result is managed pending laboratory confirmation.

Getting this right in the policy document is exactly what allows the employer to act decisively if a positive result comes back.

The policy should also explain how confirmatory laboratory testing is managed following a not-negative screening result and who is responsible for communicating the outcomes.

Consequences That Are Actually Proportionate

Here’s where a lot of policies over-correct in one direction or the other.

A proportionate framework usually looks something like this: a confirmed positive in a safety-critical role (operating machinery, driving, working at height) has more immediate consequences than the same result in a low-risk role.

First confirmed positive for someone without a prior history looks different from a repeat occurrence. Many workplace policies treat an unjustified refusal to participate in testing as a serious breach of the policy. Exactly how this is managed should be clearly explained within the policy and be consistent with employment obligations and applicable legislation.

And somewhere in that framework, there needs to be a genuine pathway to support. Not as a get-out-of-jail-free card, but as a recognition that alcohol and drug dependency are health issues. An EAP referral, access to counselling and a return-to-work process aren’t soft options. They’re often what actually resolves the underlying problem rather than just removing the person from the immediate situation.

Managers and Supervisor Responsibilities

This section is missing from a lot of policies entirely and it’s arguably the most important operational piece. A manager who suspects a worker is impaired needs to know exactly what to do.

That means: how to document observations in the moment (specific, behavioural, objective…not “seemed off”), how to remove the person from safety-critical duties without creating a confrontation in front of the team, who to call, how to initiate a reasonable cause test and what to do with the worker while results are being processed.

Managers who don’t have this clarity either do nothing (because acting feels too complicated) or they otherwise improvise in ways that create procedural problems down the track.

Supervisor training isn’t optional if the policy is going to function in practice. The document can be perfect and the programme still fails if the people responsible for applying it aren’t equipped to do it.

What Should a Workplace Drug and Alcohol Policy Include?

Building a policy from scratch with all of the above in mind takes time and a reasonable amount of expertise.

For most businesses, a well-constructed template is the smarter starting point, which is something that covers the key components correctly. It needs to include guidance notes to help adapt the language to the specific workplace and doesn’t require starting from a blank page at eleven o’clock on a Sunday night before a new principal contractor requirement kicks in Monday morning.

When developing a Workplace Drug and Alcohol policy, it is recommended to consult Safe Work Australia’s guidance, the AS/NZS 4308:2023 and AS/NZS 4760:2019 standards, and any other applicable laws and standards, such as Privacy Acts and WHS requirements. This is to ensure it is actually usable rather than merely technically compliant.

In most Australian jurisdictions, employers also have obligations to consult with workers when introducing or changing workplace health and safety measures. Consulting employees during the development or review of a drug and alcohol policy not only helps meet WHS obligations but also improves understanding and acceptance of the programme.

A well-developed workplace drug and alcohol policy should clearly explain:

why the organisation has implemented the policy
who it applies to
the roles and responsibilities of workers, supervisors and managers
when testing may occur
the testing methods used
how results will be managed
the support available to employees
how and when the policy will be reviewed.

The level of detail will vary between organisations, but every policy should provide enough information that workers understand both their responsibilities and the organisation’s expectations.

Turning the Policy Into a Working Programme

A document in a shared drive is not a drug and alcohol programme. This is perhaps the most important thing to understand about where policies fail (and they do fail, regularly in workplaces that have technically ticked the box!).

Making it real means communicating it properly. Not just emailing a PDF. But actually covering it in toolbox talks and including it in inductions in a way that actually lands and not just a signature on a form. Making sure every worker genuinely understands what’s expected and what the consequences are.

It means having the testing programme in place before the policy references it. A policy that says “random testing is conducted in accordance with AS/NZS 4308:2023”, but the business has no testing provider, no compliant devices and no chain of custody procedure is going to have a very bad day the first time someone challenges a result.

And it means reviewing the policy on a real cycle. You should do this at least annually and whenever something significant changes. This is because legislation gets updated. Standards also change (as AS/NZS 4308 did in 2023). The workplace itself evolves, and a policy written for a team of eight looks pretty thin when the business has grown to sixty people with three subcontractors on site.

Where organisations conduct their own in-house urine drug testing, the programme should include documented testing procedures, product training, quality control processes and regular reviews to ensure ongoing compliance with the relevant Australian Standards.

Under AS/NZS 4308:2023, organisations conducting on-site urine drug testing should also have documented quality control procedures to verify ongoing device performance. Quality control is now an important component of maintaining a compliant workplace testing programme.

Does your Workplace Drug and Alcohol Policy Include?

Purpose and objectives
Scope (employees, contractors and visitors)
Roles and responsibilities
Prescription medication disclosure
Testing circumstances
Testing methods
Australian Standards referenced
Chain of custody procedures
Consequences and support pathways
Manager responsibilities
Review process

How Sober Check Supports Australian Workplaces

Developing a workplace drug and alcohol policy is only the first step. Successfully implementing it requires the right testing solution, documented procedures and people who understand how the programme operates in practice.

Sober Check Australia helps organisations build practical workplace testing programmes by supplying compliant workplace drug and alcohol testing solutions including testing devices, product training, assistance with testing procedures and ongoing technical support.

Whether you’re developing a new workplace drug and alcohol policy, reviewing an existing programme or preparing for the requirements of AS/NZS 4308:2023, our team can help you choose a solution that’s practical, compliant and suited to your workplace.

Talk to the Sober Check team today to discuss the right approach for your workplace.

Australian Standards for Urine Drug Testing: AS/NZS 4308:2023 Guide

15July202615 July 2026 Becks Stratton

There’s a deadline approaching that many Australian employers don’t yet know about, and those who miss it will find themselves in a very uncomfortable position.

By November 2026, every workplace urine drug testing programme in Australia will need to meet the updated requirements under the AS/NZS 4308:2023. The standard is officially called: Procedures for Specimen Collection and the Detection and Quantification of Drugs in Urine.

It doesn’t matter whether the workplace runs mining operations in Western Australia, a logistics fleet in Queensland or a construction site in Victoria. Drug testing compliance in Australia just got a significant update and understanding what has changed isn’t exactly optional anymore.

This guide helps to break it all down.

What Changed from AS/NZS 4308:2008 to 2023

The AS/NZS 4308 standard had been around since 1995, originally published as AS 4308-1995 and Australian workplaces built their drug-testing programmes around it. In 2001, it was revised and jointly designated as AS/NZS 4308:2001. In 2008, it was updated as AS/NZS 4308:2008, which introduced provisions for on-site screening. In 2023, the standard was updated to AS/NZS 4308:2023. It included a 36-month rollover period before the 2008 standard was to be superseded. This gives everyone involved in the process time to update policies, procedures and products.

The AS/NZS 4308:2023 standard enhances workplace drug testing by lowering cut-off levels for cocaine and updating reporting terminology to “not-negative.” Science has moved forward, substances have evolved and the 2008 standard simply couldn’t keep pace with what employers were actually dealing with on-site, in the real world.

The 2023 revision, however, brought the standard into the modern era across several key areas:

The scope of substances screened for was only slightly altered (with only cocaine changing). The updated standard now better accounts for the realities of contemporary drug use with some of the key findings below:

There is a whole new appendix dedicated to Additional and optional testing – Appendix A, which covers Additional and optional testing, including setting a cut-off level for Oxycodone if it is included in a screening test.
Cut-off levels for specific drugs and compounds, depending if you are using:
- immunoassay – a biochemical test that measures the presence or concentration of a substance (analyte), including drugs, in biological samples using the specific binding between an antigen and an antibody
  or
- mass-spec screening – a highly specific analytical technique used to detect and quantify compounds, such as drugs, by sorting ions based on their mass-to-charge ratio.
It also gives a list of examples of drugs that can be tested for in consultation with a lab, such as Fentanyl and Synthetic Cannabinoids.

Collector training and competency requirements also saw meaningful updates. The standard places a strong emphasis on the qualifications of the people who are actually administering collections, not just on the labs that process the samples. That’s a change that matters a lot for employers who are increasingly relying on on-site testing programmes.

Point-of-care testing devices (such as rapid on-site screening kits) are addressed with greater specificity than before. The criteria for acceptable devices, their proper use and the handling of results have all been clarified. This should be genuinely helpful for anyone trying to run a compliant on-site programme.

Stronger Quality Control Requirements for On-Site Testing

One of the biggest operational changes introduced in AS/NZS 4308:2023 is the increased emphasis on quality control for on-site urine drug screening.

Under the previous 2008 standard, much of the quality assurance focus sat with accredited laboratories. The 2023 standard places greater responsibility on organisations that conduct workplace testing themselves by introducing defined quality-control procedures for on-site screening devices and for creatinine measurement.

This means employers can no longer simply purchase compliant urine drug testing devices and assume they remain compliant throughout their shelf life.

The testing programme itself must demonstrate that devices continue to perform as intended. The new quality control requirements include:

High-and low-control samples must be tested before a new lot of on-site drug-screening or creatinine-testing devices is put into service.
Ongoing high- and low-control testing must then be performed at least monthly for every lot of devices held in storage.
All quality control results must be documented and retained as part of the organisation’s quality records.
If a control test fails, the affected lot must be investigated and, where necessary, withdrawn from service until satisfactory performance has been demonstrated.
Organisations must also have documented procedures describing how quality control failures are managed and how the integrity of previous test results will be assessed if a failure occurs.

The standard also encourages participation in ongoing proficiency or blind testing programmes. These independently verify that collectors, devices and on-site testing processes continue to produce reliable and repeatable results over time rather than simply relying on manufacturer specifications.

For employers running their own workplace testing programme, this represents a significant shift. Compliance is no longer just about using the right urine cup or following the correct collection procedure. It now includes maintaining documented evidence that the testing devices themselves continue to perform accurately throughout their use.

New Cut-Off Levels and Detection Windows

Cut-off levels are the concentration thresholds that determine whether a sample returns a not-negative or negative result. Get them wrong (or use outdated thresholds) and the whole testing programme is built on shaky ground.

AS/NZS 4308:2023 has seen the following key changes implemented:

Key Changes in Cut-offs (2008 vs. 2023):

Cocaine Metabolites: Screening reduced from 300 ng/mL to 150 ng/mL. Confirmation dropped from 150 ng/mL to 100 ng/mL.
Benzodiazepines: Screening remains at 200 ng/mL, but the confirmation cut-off for metabolites (Nordiazepam, Oxazepam, Temazepam) has been revised to improve accuracy and reduce false positives.
Opiates, Amphetamines and THC: Cut-off levels for these substances remain consistent with the 2008 standard.

These changes across the substance classes are to better align with both current pharmacological understanding and international best practice. This matters in practice because a test calibrated to old thresholds might clear someone who shouldn’t be cleared or flag someone who shouldn’t be flagged.

Cannabis remains the most commonly detected substance in Australian workplace urine testing. Detection windows vary based on factors such as frequency of use, body composition, and the type of specimen collected. On that last note, urine is the most common specimen.

For amphetamines (including methamphetamine), the cut-off levels have not changed. The standard specifically states that it applies only to exposure, not to impairment.

Cocaine and some specific analytes for other drug classes have updated cut-off levels under the 2023 standard. If you want to test for compounds outside the ‘standard six’ (opiates, amphetamines, methamphetamine, cocaine, benzos & THC), you can use extended panel testing, such as a dip test; however, the standard notes that it should be done in consultation with a laboratory that can provide advice on what levels are consistent or inconsistent.

Any testing programme still operating off 2008 cut-off numbers needs to be updated immediately.

Not in November 2026, but now.

What is Creatinine?

Creatinine is a naturally occurring chemical waste product generated by muscle metabolism and filtered exclusively by the kidneys, which excrete it into urine. In a healthy human body, muscle mass and kidney function remain relatively stable day-to-day, so creatinine concentrations in normal urine remain within a highly predictable, consistent baseline range.

Why is it a Critical Focus in Workplace Drug Testing?

In the context of workplace drug screening, creatinine is not tracked to detect substance abuse; instead, it is utilised as the ultimate gauge of sample validity and donor integrity.

Because it is an unavoidable biological signature of human urine, tracking creatinine allows testing officers to immediately identify if a donor is attempting to cheat or tamper with the test.

Testing panels look for two major red flags:

The Absence of Creatinine (Low Readings): An abnormally low or completely absent creatinine reading indicates that the sample is not a natural human specimen. It instantly flags that the donor has either substituted their sample with synthetic “fake urine” or has consumed extreme volumes of water to flush and dilute their system below the readable drug thresholds.
Spiked Concentrations (High Readings): Conversely, an unnaturally elevated or concentrated creatinine reading suggests that it might be a heavily diluted or altered sample.

The AS/NZS 4308:2023 Enforcement

While modern urine cups utilise a matrix of integrity checks – including pH scales, specific gravity, and temperature strips (which have been expanded under the 2023 standard to read from 32°C to 38°C) – the new standard singles out creatinine for rigorous enforcement.

Under the AS/NZS 4308:2023 regulations, creatinine testing panels can no longer be passive add-ons. Manufacturers must be able to demonstrate that their devices have been independently verified as fit for purpose in accordance with Appendix B of AS/NZS 4308:2023. In addition, organisations conducting on-site testing must now perform ongoing high and low creatinine quality control testing to verify continued device performance.

Chain of Custody Requirements

Chain of custody is where a lot of well-intentioned drug testing programmes quietly fall apart. It sounds like a legal formality, but it’s actually the backbone of any defensible result.

If a positive test ever ends up in a Fair Work Commission hearing or an internal dispute process, chain-of-custody documentation is what makes or breaks the case.

AS/NZS 4308:2023 reinforces and clarifies the chain of custody requirements present in the 2008 standard, with greater specificity regarding documentation, handling and transfer procedures.

From the moment a specimen is collected, every step needs to be documented. Who collected it, when, reason for testing, unique donor identifiers, screening results (if the sample is screened), and donor acknowledgement that the sample is theirs. All of it needs to be traceable without gaps.

The standard specifies the use of tamper-evident specimen containers and requires that chain-of-custody forms accompany specimens throughout the process.

For on-site testing, chain-of-custody requirements also apply to the screening process. A not-negative screening result that isn’t properly documented and handled in accordance with the standard cannot be relied upon if challenged.

That’s a very real risk for employers who treat on-site testing as a quick, informal process rather than a documented procedure. Laboratories may also refuse to run tests on samples that do not meet the chain-of-custody protocol.

Employer Compliance Checklist

Getting compliant with AS/NZS 4308:2023 isn’t a job to put aside for an afternoon; however, it is absolutely manageable with the right roadmap.

Here’s what every employer should be working through before that November 2026 deadline:

Review and update the workplace drug and alcohol policy: The policy needs to reference the current standard, not the 2008 version. If the document still cites AS/NZS 4308:2008, it needs to be updated.
Audit current testing procedures against the 2023 requirements: Cut-off levels, collection procedures and documentation practices are all ways to compare what’s happening on the ground with what the standard actually requires.
Verify laboratory accreditation: Confirming that the laboratory processing the tests holds current NATA accreditation under the updated standard is non-negotiable.
Check the collector’s qualifications and training: The people administering collections need to meet the competency requirements outlined in the 2023 standard. Review their credentials and identify any gaps.
Review on-site testing device compliance: If rapid on-site screening devices are part of the programme, confirm they meet the performance criteria specified in AS/NZS 4308:2023.
Update chain-of-custody documentation: The forms, procedures and handling practices will all need to align with the current standard’s requirements.
Train managers and supervisors: The people making reasonable-cause testing decisions need to understand what the updated standard means for their roles.
Implement an onsite quality control programme: If your organisation conducts on-site urine drug testing, ensure routine high and low control testing, lot verification, documentation and quality control procedures comply with AS/NZS 4308:2023.

What Happens If You’re Not Compliant by the November 2026 Deadline

Here’s the uncomfortable part. A drug testing programme that doesn’t comply with AS/NZS 4308:2023 after the November 2026 deadline isn’t just technically out of date. It also creates genuine legal and operational exposure.

In safety-critical industries where drug testing is a regulatory requirement, non-compliant testing procedures can undermine the legal defensibility of results. An employee who is dismissed following a positive result from a non-compliant test has very real grounds to challenge that outcome. And, depending on the industry and jurisdiction, there may also be direct regulatory consequences for organisations whose safety management systems reference testing standards they don’t actually meet.

Beyond the legal risk, there’s a practical safety argument. The 2023 standard exists because the 2008 standard wasn’t keeping pace with the actual landscape of workplace drug use. Operating under outdated cut-offs and procedures means the testing programme may not catch what it’s supposed to. It’s not necessarily drugs at the workplace; it’s about not being at work while impaired, thereby increasing the risk of an unsafe work environment. That’s a risk that ultimately shows up as workplace incidents, not compliance notices.

The November 2026 deadline feels like it’s a long way off. It isn’t. Updating a workplace drug testing programme (and especially in a large organisation) takes time. Policy reviews, supplier conversations, staff training and documentation overhauls are each significant processes. Getting each process underway now is the move that makes the deadline feel manageable.

Leaving it for late 2026 is precisely a move that could make it feel like a crisis!

Are you ready to make sure your workplace drug testing programme meets every requirement under AS/NZS 4308:2023?

The team at Sober Check Australia are built for exactly this, walking employers through the updated standard, identifying gaps in current programmes and putting a clear path to compliance in place before the deadline arrives.

Get in touch with the team today to learn how we can help get your testing programme in place.

Drug Testing at Mine Sites: How it Underpins Site Safety

17March202618 March 2026 Becks Stratton

Australian mining operates in one of the most high-risk industrial environments in the country. Employing more than 300,000 Australians in remote and hazardous locations, the sector depends on precision, coordination and constant situational awareness to operate safely.

Explosives handling, heavy fleet movement, underground operations and underground and open-cut operations create an extremely narrow margin for error across daily shifts.

In this environment, impairment caused by drugs or alcohol is not a minor concern but a direct and immediate threat to life. For modern operators, mining safety Australia begins with ensuring every worker is genuinely fit for duty before stepping onto site and commencing high-risk tasks under strict procedural controls.

Beyond the Law: The Moral Case for Testing

While regulatory compliance is essential, drug and alcohol testing in mining goes far beyond meeting legal obligations. As highlighted by AusHealth, testing should never be viewed as punitive or designed to catch people out after mistakes occur. Instead, it is a preventative safety measure that protects workers, contractors and surrounding communities before incidents happen. When incidents occur on mine sites, the consequences extend well beyond operational disruption or production delays. Families, colleagues and regional communities often carry the long-term emotional, social and economic impacts of serious injuries or fatalities that could have been avoided through earlier intervention.

Shifting from a blame-based mindset to a care-based safety culture reframes testing as a support mechanism rather than a disciplinary tool used after harm occurs. It signals that employers are committed to Zero Harm, recognising impairment risks early and intervening before accidents occur. This approach strengthens trust between workers and management, reinforces shared responsibility for safety outcomes and aligns with contemporary expectations of ethical leadership across the Australian resources sector.

The FIFO Factor: Mental Health and Substance Use

The structure of modern mining work presents unique challenges that increase the risk of substance misuse. Fly-in, fly-out arrangements, extended rosters, compressed work cycles and prolonged isolation from family and social support networks place significant psychological strain on workers. Research indicates that approximately 20% of the mining workforce experiences psychological or social difficulties linked directly to these conditions and work patterns.

These pressures are reflected in substance use data. Alarmingly, 45.7% of males working in coal mining report risky or hazardous drinking behaviours during off-shift periods. Fatigue, loneliness, disrupted sleep and cumulative stress can compound decision-making impairment, especially when combined with alcohol or drugs. A well-designed FIFO drug and alcohol policy acknowledges these realities and integrates testing with education, mental health support, fatigue management and early intervention strategies rather than relying solely on disciplinary responses.

Regulatory Framework: Navigating State and National Laws

Drug and alcohol testing at mine sites is firmly embedded within Australia’s work health and safety framework. At a national level, the Work Health and Safety (WHS) Act 2011 imposes a duty of care on employers to take all reasonably practicable steps to eliminate or minimise risks, including impairment-related hazards. Failure to manage fitness for work can expose Site Senior Executives to significant legal, financial and reputational consequences under enforcement action.

State-based regulations reinforce this obligation. In Western Australia, the WHS (Mines) Regulations 2022 explicitly require mine operators to manage hazards related to alcohol and other drugs. Queensland’s Coal Mining Safety and Health Act 1999 mandates that workers must be fit for work at all times, while New South Wales’ WHS (Mines and Petroleum Sites)Regulation 2014 places similar expectations on duty holders. Together, these frameworks make drug testing mine sites a non-negotiable element of compliance across all major mining jurisdictions.

Implementation: Best Practices for 2026

As mining operations evolve, so too must impairment management strategies. Best practice for 2026 points toward a blended approach combining random and targeted testing. Random testing acts as a strong deterrent, while targeted testing following incidents or reasonable cause ensures risks are addressed promptly, fairly and consistently. This balance supports operational integrity without creating a culture of surveillance or mistrust on site.

Education and rehabilitation are equally critical. Integrating testing programs with Employee Assistance Programs (EAP) allows workers who return non-negative results to access confidential counselling and treatment pathways. This reinforces the principle that fitness for work mining programmes exist to keep people safe, supported and productive rather than to terminate employment unnecessarily or create fear-based compliance.

Technology also plays a defining role, particularly in remote environments where laboratory access is limited or delayed. Using high-quality, certified testing equipment ensures results are accurate, defensible and compliant with Australian Standards. Providers such as Sober Check supply industrial-grade breathalysers and oral fluid (saliva) drug testing devices designed specifically for harsh site conditions, supporting reliable on-site decision-making. Mining operators can explore these solutions and learn more about Sober Check’s end-to-end safety services.

Conclusion: Testing as the Bedrock of Site Integrity

Drug and alcohol testing is not simply a regulatory checkbox for Australian mining; it is a foundational element of site integrity, workforce protection and operational resilience. While compliance with legislation is essential, a mature safety culture recognises testing as part of a broader commitment to Zero Harm. By addressing FIFO pressures, supporting mental health and implementing robust, fair testing protocols, operators actively safeguard lives, reputations and long-term productivity.

As expectations rise toward 2026, Site Senior Executives and Health and Safety Representatives should proactively review their drug and alcohol policies, testing methodologies, governance processes and equipment standards using contemporary guidance. Investing in reliable technology and professional support strengthens fitness-for-work systems and demonstrates genuine care for people.

Mining organisations seeking guidance or upgraded testing infrastructure are encouraged to connect with Sober Check through their contact channels to ensure their sites remain safe, compliant, resilient and future-ready across all operational contexts nationwide, reinforcing industry-wide accountability.

Workplace Drug Testing in Australia: Trends & 2026 Insights

26February20269 March 2026 Becks Stratton

Introduction: The State of Play in 2026

Workplace drug testing in Australia has become a critical component of organisational risk management as employers respond to evolving substance use patterns and heightened Work Health and Safety (WHS) obligations. According to recent data from The Drug Detection Agency (TDDA), the national workplace drug test positivity rate reached 3.1% in the September quarter. While this figure may appear stable at a glance, it represents thousands of individual safety decisions being made across Australian worksites every week.

Importantly, this data reflects more than isolated incidents. It highlights a sustained post-pandemic baseline in which substance use has become more diversified, socially normalised, and less predictable. Hybrid work models, increased job stress, and blurred boundaries between work and personal time have all contributed to this shift.

As a result, workplace drug testing Australia-wide is no longer viewed as a reactive compliance exercise. Instead, it is increasingly recognised as a proactive safety strategy that protects employees, contractors, business continuity, and organisational reputation.

The “Summer Surge”: Why Safety Doesn’t Take a Holiday

Australian employers face a recurring seasonal risk commonly referred to as the “summer surge.” Analysis reported by Human Capital Australia shows that positive workplace drug tests consistently rise during warmer months, particularly around public holidays, Christmas shutdowns and extended leave periods.

Why Do Drug Tests Increase in Summer?

The Australian “silly season” creates ideal conditions for increased substance use. End-of-year celebrations, social events, and relaxed routines often lead to higher consumption of alcohol and illicit drugs. When employees return to work, residual impairment can still be present, especially in safety-critical roles.

Several contributing factors explain this seasonal pattern:

• Increased social and recreational drug use during holidays
• Longer detection windows overlapping return-to-work periods
• Reduced routine and sleep disruption
• Informal or relaxed management oversight during summer

While goodwill and flexibility are important, WHS compliance requires consistency. Drug testing programs must remain active during peak risk periods rather than being reduced when risk is highest.

The Substance Shift: Beyond the Usual Suspects

Substance use trends in Australian workplaces have shifted significantly over recent years. What was once dominated by a narrow range of drugs has expanded into a more complex and varied profile that affects multiple industries and role types.

The Cocaine Climb

One of the most notable drug testing trends 2026 data has revealed is the steady increase in cocaine detection. Cocaine now represents approximately 8.5% of positive workplace drug tests and is no longer confined to senior or traditionally white-collar environments.

Improved availability, reduced stigma, and expanded distribution networks have contributed to its presence across construction, transport, mining, and professional services. While cocaine is often perceived as a “functional” stimulant, it significantly impairs judgement, increases risk-taking behaviour and elevates the likelihood of workplace incidents.

ATS Dominance Across Industries

Amphetamine-Type Substances (ATS), including methamphetamine, remain the most dominant drugs detected in Australian workplaces. In 2026 data, ATS appear in 53.2% of all positive tests, representing a 6.3% year-on-year increase.

The WHS risks associated with ATS use are severe and well documented. Common impacts include:

• Overconfidence and impaired judgement
• Fatigue crashes following stimulant use
• Increased aggression or agitation
• Reduced risk perception

In high-risk environments involving machinery, vehicles, or complex operational tasks, these effects can be catastrophic. This dominance reinforces the importance of random drug testing workplace programs as a core deterrent strategy.

Cannabis (THC): Presence Versus Impairment

Cannabis continues to be detected in 46.5% of positive workplace drug tests, also increasing by 6.3%. As social attitudes and legislation evolve, employers face ongoing challenges balancing individual freedoms with safety obligations.

The central issue remains the distinction between presence and impairment. THC can remain detectable long after consumption, yet employers must still assess fitness for work based on role-specific risk. Clear policy wording, role-based thresholds and consistent enforcement are essential for managing cannabis-related risk fairly and defensibly.

Fast Facts: Australian Workplace Drug Testing 2026

• Overall positivity rate: 3.1%
• ATS/Methamphetamine: 53.2% of positive tests
• Cannabis (THC): 46.5% of positive tests
• Cocaine: 8.5% and steadily rising
• Opioids: 16% with a gradual decline

Modernising the Policy: Return-to-Work & Random Protocols

Many workplace drug and alcohol policies currently in use were designed for a less complex risk environment. Annual testing or post-incident testing alone is no longer sufficient to meet modern WHS expectations.

In 2026, leading organisations are adopting comprehensive approaches that include:

Structured random drug testing workplace programs
Mandatory return-to-work testing following incidents or extended leave
Clear escalation pathways and documentation
Consistent application across all roles and seniority levels

Random testing acts as a proven deterrent, while return-to-work protocols support accountability, recovery and transparency. Together they form a defensible safety framework aligned with contemporary WHS standards.

Manager capability is equally critical. Leaders must be trained to recognise impairment indicators, understand procedures, and act decisively. The ability to “notice and act” is now a core leadership competency, particularly in safety-sensitive environments.

This is where Sober Check Australia provides value beyond testing hardware, supporting organisations with compliant equipment, practical guidance, and policy-aligned frameworks that help businesses enforce drug and alcohol programs consistently and confidently.

Technical Standards: Oral Fluid vs Urine

Australian drug testing programs must comply with recognised standards. Oral fluid/saliva testing is governed by AS/NZS 4760:2019, while urine testing follows AS/NZS 4308:2023.

Urine testing remains valuable for identifying historical use patterns. However, oral fluid testing is increasingly preferred in 2026 due to its ability to detect recent use, making it more relevant for real-time safety decisions.

Employers can access compliant workplace testing solutions through Sober Check Australia’s range of Drug Testing Kits, Saliva Tests, and Alcohol Breathalysers, designed to support Australian drug testing standards and WHS compliance.

Key reasons for the shift toward oral fluid testing include:

• Detection of recent drug use
• Faster on-site collection
• Reduced privacy concerns
• Greater alignment with impairment risk

Conclusion: Building a Resilient Workforce

Workplace drug testing Australia-wide is no longer about compliance alone. It is about building a resilient, safety-focused workforce capable of adapting to seasonal pressures and evolving substance trends.

As summer approaches and positivity rates rise, now is the ideal time for employers to:

• Audit existing drug testing kits
• Review and update drug and alcohol policies
• Reinforce manager training and accountability
• Ensure alignment with WHS compliance obligations

Organisations that act proactively will be better positioned to reduce incidents, protect employees and maintain operational integrity. To stay ahead of drug testing trends 2026, businesses are encouraged to contact Sober Check Australia today to learn more about compliant testing solutions, policy support and training designed for modern Australian workplaces.